top of page

End-of-year review: CNS & Rare Disease

‘Although it has definitely been a tricky and challenging year for neuroscience – and biopharma in general – there have been some amazing successes that are still worth celebrating.’


Working within the CNS & Rare Disease space for our Life Sciences team, Paula Doust Alba has had a busy year. In this video, she gives us her end-of-year review for 2023 – and while it hasn’t always been plain sailing, breakthroughs in Alzheimer’s have been particularly gratifying to note.


Check out this clip to hear Paula reflect on the demand for clinical talent and experienced CMOs, fundraising and development breakthroughs – in addition to her predictions for 2024!




Comments


bottom of page